Firing of Replication Origins Is Disturbed by a CDK4/6 Inhibitor in a pRb-Independent Manner

Area of Science:

• Cell Biology
• Molecular Oncology
• Cancer Therapeutics

Background:

• CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) are approved for HR+ breast cancer, primarily targeting the pRb-E2F pathway.
• Existing research focuses on CDK4/6 inhibition's effects in pRb-proficient cells, leading to cell cycle arrest.
• Emerging evidence suggests CDK4/6 inhibitors have pRb-independent functions requiring further investigation.

Purpose of the Study:

• To investigate the effects of palbociclib on DNA replication in pRb-deficient cancer cells.
• To characterize the impact of palbociclib on origin firing and replication fork dynamics.
• To explore potential therapeutic applications of palbociclib beyond its known mechanism.

Main Methods:

• Utilized pRb-deficient cell lines treated with palbociclib.
• Assessed DNA synthesis levels and cell cycle progression.
• Analyzed DNA replication timing and replication fork density.
• Investigated the loading of Pre-initiation complex (Pre-IC) proteins onto chromatin.

Main Results:

• Palbociclib treatment reduced DNA synthesis in pRb-deficient cells without inducing cell cycle arrest.
• The drug disturbed the temporal program of DNA replication and decreased replication fork density.
• Defects in Pre-IC protein loading on chromatin were observed, indicating impaired DNA replication initiation.
• Cytotoxic effects on cell viability were noted in the absence of pRb.

Conclusions:

• Palbociclib exhibits pRb-independent effects on DNA replication dynamics.
• Impaired origin firing and reduced DNA synthesis contribute to palbociclib's cytotoxicity in pRb-deficient contexts.
• These findings suggest potential for palbociclib in combination therapies targeting genomic instability in pRb-deficient cancers.